Harrow: The Triesence Relaunch
Portfolio Pulse from
Harrow has relaunched Triesence, a preservative-free corticosteroid, to meet a critical need in ophthalmology. The product's unique formulation offers a safer alternative to existing treatments, positioning Harrow for significant market growth.
December 14, 2024 | 5:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Harrow's relaunch of Triesence, a preservative-free corticosteroid, positions the company for significant market growth in ophthalmology by addressing a critical unmet need.
The relaunch of Triesence addresses a critical unmet need in ophthalmology, offering a safer and more effective treatment option. This positions Harrow for significant market growth, especially with the target of over 500,000 units annually.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100